通过活衰减的SARS-CoV-2鼻腔疫苗改善粘膜免疫力
Jason Yeung1, Tian Wang2, Pei-Yong Shi3
1Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Current opinion in virology
|August 21, 2023
概括
下一代鼻腔疫苗旨在通过诱导粘膜免疫来预防SARS-CoV-2感染和传播. 活减弱病毒疫苗显示出增强保护的潜力,特别是在以前用mRNA疫苗接种的个体中.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 早期的COVID-19疫苗有效地减少了疾病的严重程度.
- 需要下一代疫苗来预防严重急性呼吸综合征相关的冠状病毒2 (SARS-CoV-2) 感染和传播.
- 粘膜免疫是防止病毒进入和传播的关键目标.
研究的目的:
- 审查活体减弱SARS-CoV-2鼻内疫苗的潜在益处和考虑因素.
- 为了突出一种活体减弱的SARS-CoV-2鼻内疫苗平台的发展.
- 探索诱导粘膜免疫和混合免疫的方法.
主要方法:
- 审查关于粘膜疫苗平台的当前研究.
- 讨论用于疫苗开发的活减弱病毒技术.
- 在接种疫苗和先前感染的个体中探索混合免疫诱导.
主要成果:
- 活衰减的SARS-CoV-2病毒是注射鼻腔疫苗的一个有希望的平台.
- 通过鼻子给药可以诱导粘膜免疫力,可能防止感染和传播.
- 活体减弱疫苗可能会诱导先前接受mRNA疫苗接种的个体产生混合免疫力.
结论:
- 活衰减的SARS-CoV-2鼻内疫苗为下一代COVID-19预防提供了一个潜在的战略.
- 需要进一步开发以评估这些粘膜疫苗的安全性和有效性.
- 诱导广泛的免疫力,包括粘膜和混合免疫力,是关键目标.
更多相关视频
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
10.7K
10:39Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
12.7K
相关概念视频
01:29Microorganisms in Medicine and Therapeutics
54
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
54
01:51Vaccinations
44.7K
Overview
44.7K